Oppenheimer Summit for Emerging Biotechnology (Montauk)


The Emerging Life Sciences Summit hosted by Oppenheimer will be on July 20th, 2022 in Montauk, NY.  This yearly conference brings together the who’s who of Life Science executives, Investment Banking leaders, Investors and other professionals.

This event will feature 1-on-1 on meetings with companies focused in the biotechnology space as well as panelists discussing advances and challenges in the industry.



Eric Richman, CEO of Gain Therapeutics has been invited to attend this prestigious conference.




“Our thanks to Oppenheimer and Co. for organizing the Montauk Summit for Emerging Biotechnology. Growth in our industry over the past several years has resulted in a wealth of innovation that will drive tomorrow’s medical advances. By bringing together thought leaders from all facets of our industry we will continue our forward momentum during challenging times such as these and ensure biotech remains a driving force of innovation.

We are honored to have been selected to participate in this invitation-only event and have the opportunity to network with highly targeted life sciences investors and stakeholders. A number of very timely and relevant panel discussions have been organized focusing on emerging issues, including, the world of biopharma impact investing, current capital markets perspective in this uncertain life sciences environment, new realities of biotech market approvals and novel approaches to market access. We look forward to a successful and enriching Oppenheimer summit.”

The Discussions will be around these themes :

▪ Biopharma Impact Investing
▪ Pharma / Business Development
▪ Investing in an Uncertain Life Sciences Environment: A Capital Markets Perspective
▪ New Realities Impacting Biotechnology Market Approvals and Entries Ahead
▪ Biotech Commercialization and Novel Approaches To Market Access
Companies Presenting include :

▪ Scorpion Therapeutics
▪ Biohaven
▪ Lumanity
▪ Merck
▪ Tempus
▪ Sun Pharama
Investors Presenting Include :

▪ Oppenheimer
▪ Brightedge
▪ MD Anderson Fund
▪ Blackstone
▪ Logos Capital
▪ MPM BioImpact Capital
▪ Upstream Partners
▪ Perceptive Advisors